{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Antibody", "Drug resistance", "Epitopes", "SARS-CoV-2", "Spike protein"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35461370", "DateRevised": {"Year": "2023", "Month": "11", "Day": "05"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "04", "Day": "24"}], "Language": ["eng"], "ELocationID": ["12", "10.1186/s43556-022-00074-3"], "Journal": {"ISSN": "2662-8651", "JournalIssue": {"Volume": "3", "Issue": "1", "PubDate": {"Year": "2022", "Month": "Apr", "Day": "24"}}, "Title": "Molecular biomedicine", "ISOAbbreviation": "Mol Biomed"}, "ArticleTitle": "Omicron-included mutation-induced changes in epitopes of SARS-CoV-2 spike protein and effectiveness assessments of current antibodies.", "Pagination": {"StartPage": "12", "MedlinePgn": "12"}, "Abstract": {"AbstractText": ["The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading globally and continues to rage, posing a serious threat to human health and life quality. Antibody therapy and vaccines both have shown great efficacy in the prevention and treatment of COVID-19, whose development progress and adaptation range have attracted wide attention. However, with the emergence of variant strains of SARS-CoV-2, the neutralization activity of therapeutic or vaccine-induced antibodies may be reduced, requiring long-term virus monitoring and drug upgrade in response to its evolution. In this paper, conformational changes including continuous epitopes (CPs), discontinuous epitopes (DPs) and recognition interfaces of the three representative SARS-CoV-2 spike protein (SP) mutants (i.e., the Delta (B.1.617.2), Mu (B.1.621) and Omicron (B.1.1.529) strains), were analyzed to evaluate the effectiveness of current mainstream antibodies. The results showed that the conformation of SP wild type (WT) and mutants both remained stable, while the local antigenic epitopes underwent significant changes. Sufficient flexibility of SP CPs is critical for effective antibody recognition. The DPs of Delta, Mu and Omicron variants have showed stronger binding to human angiotensin converting enzyme-2 (hACE2) than WT; the possible drug resistance mechanisms of antibodies against three different epitopes (i.e., NTD_DP, RBD1_DP and RBD2_DP) were also proposed, respectively; the RBD2 of Delta, NTD of Mu, NTD and RBD2 of Omicron are deserve more attention in the subsequent design of next-generation vaccines. The simulation results not only revealed structural characteristics of SP antigenic epitopes, but also provided guidance for antibody modification, vaccine design and effectiveness evaluation."], "CopyrightInformation": "\u00a9 2022. The Author(s)."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Tumor Targeted and Immune Therapy, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, 610041, China."}], "LastName": "Guo", "ForeName": "Du", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, School of Pharmacy, Chengdu University, Chengdu, 610106, China."}], "LastName": "Duan", "ForeName": "Huaichuan", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Tumor Targeted and Immune Therapy, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, 610041, China."}], "LastName": "Cheng", "ForeName": "Yan", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, School of Pharmacy, Chengdu University, Chengdu, 610106, China."}], "LastName": "Wang", "ForeName": "Yueteng", "Initials": "Y"}, {"Identifier": ["0000-0001-7367-3968"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, School of Pharmacy, Chengdu University, Chengdu, 610106, China. hjpcdu@163.com."}], "LastName": "Hu", "ForeName": "Jianping", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Tumor Targeted and Immune Therapy, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, 610041, China. shihb@scu.edu.cn."}], "LastName": "Shi", "ForeName": "Hubing", "Initials": "H"}], "GrantList": [{"GrantID": "2018KF006", "Agency": "State Administration of Traditional Chinese Medicine of the People's Republic of China", "Country": ""}, {"GrantID": "2019YFH0054", "Agency": "Sichuan Science and Technology Program", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Singapore", "MedlineTA": "Mol Biomed", "NlmUniqueID": "9918283581406676", "ISSNLinking": "2662-8651"}, "CoiStatement": "No conflict of interest exists in the submission of this manuscript. I would like to declare on behalf of my co-authors that the work described was original research that has not been published previously, and is not under consideration for publication elsewhere, in whole or in part. All the authors listed have approved the manuscript that is enclosed. All the authors declare no conflict of interest, financial or otherwise."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2021;395(10223):470\u2013473. doi: 10.1016/S0140-6736(20)30185-9.", "ArticleIdList": ["10.1016/S0140-6736(20)30185-9", "PMC7135038", "31986257"]}, {"Citation": "Li Y, Undurraga EA , Zubizarreta J R. Efficacy of localized lockdowns in the SARS-CoV-2 pandemic. medRxiv. 2020;1:1\u201320. doi: 10.1101/2020.08.25.20182071"}, {"Citation": "Martellucci CA, Flacco ME, Cappadona R, Bravi F, Mantovani L, Manzoli L. SARS-CoV-2 pandemic: an overview. Adv in Biol Regul. 2020;77:100736. doi: 10.1016/j.jbior.2020.100736.", "ArticleIdList": ["10.1016/j.jbior.2020.100736", "PMC7832554", "32773099"]}, {"Citation": "Johns Hopkins University. COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE). 2021. https://arcg.is/0fHmTX). Accessed 07 Apr 2021."}, {"Citation": "Ozono S, Zhang Y, Ode H, Sano K, Tan TS, Imai K, et al. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. Nat Commun. 2021;12(1):848\u2013856. doi: 10.1038/s41467-021-21118-21.", "ArticleIdList": ["10.1038/s41467-021-21118-21", "PMC7870668", "33558493"]}, {"Citation": "Swapnil M, Mindermann S, Sharma M, Whittaker C, Mellan TA, Wilton T, et al. Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England. eClin Med. 2021;39:2589\u20132597. doi: 10.1016/j.eclinm.2021.101064.", "ArticleIdList": ["10.1016/j.eclinm.2021.101064", "PMC8349999", "34401689"]}, {"Citation": "Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 16. 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/994839/Variants_of_Concern_VOC_Technical_Briefing_16.pdf. Accessed 24 June 2021."}, {"Citation": "Uriu K, Kimura I, Shirakawa K, Takaori-kondo A, Nakada T, Kaneda A, et al. Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera. New Engl J Med. 2021;385(25):2397\u20132399. doi: 10.1056/ENJMc2114706.", "ArticleIdList": ["10.1056/ENJMc2114706", "PMC8609602", "34731554"]}, {"Citation": "James N, Menzies M, Radchenko P. COVID-19 second wave mortality in Europe and the United States. Chaos. 2021;31(3):031105. doi: 10.1063/5.0041569.", "ArticleIdList": ["10.1063/5.0041569", "33810707"]}, {"Citation": "Ye T, Zhong Z, Garc\u00eda-Sastre A, Schotsaert M, Geest BG. Current status of COVID-19 (Pre) Clinical Vaccine Development. Angew Chem Int Ed. 2020;59(43):18885\u201318897. doi: 10.1002/anie.202008319.", "ArticleIdList": ["10.1002/anie.202008319", "PMC7405471", "32663348"]}, {"Citation": "World Health Organization (WHO). COVID-19 Vaccine Tracker and Landscape. 2021. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccine. Accessed 10 Nov 2021."}, {"Citation": "Cohn BA, Cirillo PM, Murphy CC, Krigbaum NY, Wallace AW. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science. 2021;375(6578):331\u2013336. doi: 10.1126/science.abm0620.", "ArticleIdList": ["10.1126/science.abm0620", "PMC9836205", "34735261"]}, {"Citation": "Wesley H, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, et al. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions. Morbid Mortal W. 2021;70(38):1337\u20131343. doi: 10.15585/mmwr.mm7038e1.", "ArticleIdList": ["10.15585/mmwr.mm7038e1", "PMC8459899", "34555004"]}, {"Citation": "Chen L, Xiong J, Bao L, Yuan S. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398\u2013400. doi: 10.1016/S1473-3099(20)30141-9.", "ArticleIdList": ["10.1016/S1473-3099(20)30141-9", "PMC7128218", "32113510"]}, {"Citation": "Ryan BJ, McCreary EK, Wadas RJ, Kip KE, Marroquin OC, Minnier T, et al. Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection. Open Forum Infect Di. 2021;8(7):1\u20138. doi: 10.1093/ofid/ofab254.", "ArticleIdList": ["10.1093/ofid/ofab254", "PMC8241472", "34250192"]}, {"Citation": "Yanyun D, Shi R, Zhang Y, Duan X, Li L, Zhang J, et al. A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants. Nat Commun. 2021;12(5000):1\u20131110. doi: 10.1038/s41467-021-25331-x.", "ArticleIdList": ["10.1038/s41467-021-25331-x", "PMC8371079", "34404805"]}, {"Citation": "Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, et al. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane DB Syst Rev. 2021;5:1\u2013274. doi: 10.1002/14651858.CD013825.", "ArticleIdList": ["10.1002/14651858.CD013825", "PMC8411904", "34473343"]}, {"Citation": "Food and Drug Administration (FDA). Emergency Use Authorization. 2021. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#abouteuas. Accessed December 25, 2021."}, {"Citation": "Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Bioph Res Co. 2020;525(1):135\u2013140. doi: 10.1016/j.bbrc.2020.02.071.", "ArticleIdList": ["10.1016/j.bbrc.2020.02.071", "PMC7092824", "32081428"]}, {"Citation": "Cai Y, Zhang J, Xiao T, Peng H, Sterling SM, Walsh JRRM, et al. Distinct conformational states of SARS-CoV-2 spike protein. Science. 2020;369(6511):eabd4251. doi: 10.1126/science.abd4251.", "ArticleIdList": ["10.1126/science.abd4251", "PMC7464562", "32694201"]}, {"Citation": "Shang J, Wan Y, Luo C, Li F. Cell entry mechanisms of SARS-CoV-2. P Natl A Sci India A. 2020;117(21):202003138. doi: 10.1073/pnas.2003138117.", "ArticleIdList": ["10.1073/pnas.2003138117", "PMC7260975", "32376634"]}, {"Citation": "Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271\u2013280. doi: 10.1016/j.cell.2020.02.052.", "ArticleIdList": ["10.1016/j.cell.2020.02.052", "PMC7102627", "32142651"]}, {"Citation": "Zheng M, Song L. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. Cell Mol Immunol. 2020;17:536\u2013538. doi: 10.1038/s41423-020-0385-z.", "ArticleIdList": ["10.1038/s41423-020-0385-z", "PMC7091851", "32132669"]}, {"Citation": "Ejemel M, Li Q, Hou S, Schiller ZA, Tree JA, Wallace A, et al. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. Nat Commun. 2020;11(1):4189\u20134197. doi: 10.1038/s41467-020-18058-8.", "ArticleIdList": ["10.1038/s41467-020-18058-8", "PMC7442812", "32826914"]}, {"Citation": "World Health Organization (WHO). Tracking SARS-CoV-2 variants. 2021. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants. Accessed 1 July 2021."}, {"Citation": "Alizon S, Haim-Boukobza S, Foulongne V, Verdurme L, Sofonea M T. Rapid spread of the SARS-CoV-2 Delta variant in some French regions. Euro Surveill. 2021;26(28). doi: 10.2807/1560-7917.ES.2021.26.28.2100573.", "ArticleIdList": ["PMC8284044", "34269174"]}, {"Citation": "Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreia I. SARS-CoV-2 B. 1.617. 2 Delta variant replication and immune evasion. Nature. 2021;599(7883):114\u2013119. doi: 10.1038/s41586-021-03944-y.", "ArticleIdList": ["10.1038/s41586-021-03944-y", "PMC8566220", "34488225"]}, {"Citation": "Uriu K, Kimura I, Shirakawa K, Akifumi TK, Kei S. Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine Serum. New Engl J Med. 2021;385(25). doi: 10.1056/NEJMc2114706.", "ArticleIdList": ["PMC8609602", "34731554"]}, {"Citation": "GISAID. hCoV-19 data sharing via GISAID. 2021. https://www.gisaid.org/. Accessed 24 May 2021."}, {"Citation": "Laiton DK, Franco-Mu\u00f1oz C, \u00c1lvarez-D\u00edaz DA, Hector AR, Jose AU, Diego AP. Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2. Infect, Genet and Evol. 2021;95:105038. doi: 10.1101/2021.05.08.21256619.", "ArticleIdList": ["10.1101/2021.05.08.21256619", "PMC8364171", "34403832"]}, {"Citation": "Snell LB, Cliff PR, Charalampous T, Adela AM, Ebie S, Sehmi JK, et al. Rapid genome sequencing in hospitals to identify potential vaccine-escape SARS-CoV-2 variants. Lancet Infect Dis. 2021;21(10):1351\u20131352. doi: 10.1016/S1473-3099(21)00482-5.", "ArticleIdList": ["10.1016/S1473-3099(21)00482-5", "PMC8363224", "34399091"]}, {"Citation": "Dhar R, Alukdar J, Nayek A, Ajmeriya S, Kumar A, Karmakar S, et al. Unveiling the omicron B.1.1. 529: the variant of concern that is rattling the globe. Asian J Med Sci. 2022;13(1):166\u2013168. doi: 10.3126/ajms.v13i1.41117.", "ArticleIdList": ["10.3126/ajms.v13i1.41117"]}, {"Citation": "COVID. COVID Quickly, Episode 21: Vaccines against Omicron and Pandemic Progress. https://www.scientificamerican.com/podcast/episode/covid-quickly-episode-21-vaccines-against-omicron-and-pandemic-progress/. Accessed 17 Dec 2021."}, {"Citation": "UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 29. 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1036324/Technical_Briefing_29_published_26_November_2021.pdf. Accessed 26 Nov 2021."}, {"Citation": "World Health Organization (WHO). Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern. Accessed 26 Nov 2021."}, {"Citation": "GOV. UK. Oral Statement on B.1.1.529 variant. 2021. https://www.gov.uk/government/speeches/oral-statement-on-b11529-variant. Accessed 26 Nov 2021."}, {"Citation": "Chin AWH, Chu JTS, Perera MRA, Kpyh A, Hly A, Mcwc A, et al. Stability of SARS-CoV-2 in different environmental conditions. Lancet Microbe. 2020;1(1):e10. doi: 10.1016/S2666-5247(20)30003-3.", "ArticleIdList": ["10.1016/S2666-5247(20)30003-3", "PMC7214863", "32835322"]}, {"Citation": "Cai Y, Zhang J, Xiao T, Peng H, Chen B. Distinct conformational states of SARS-CoV-2 spike protein. Science. 2020;369(6511):1586\u20131592. doi: 10.1101/2020.05.16.099317.", "ArticleIdList": ["10.1101/2020.05.16.099317", "PMC7464562", "32694201"]}, {"Citation": "Yu W, Wu X, Ren J, Jia Y, Zhang XC, Wang YM, et al. Mechanistic Insights to the Binding of Antibody CR3022 Against RBD from SARS-CoV and HCoV-19/SARS-CoV-2: A Computational Study. Comb Chem High T Scr. 2020;23(7). doi: 10.2174/1386207323666201026160500.", "ArticleIdList": ["33106140"]}, {"Citation": "Yuan M, Wu NC, Zhu X, Lee CC, Ray TY, Hubin L, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020;368(6491):630\u2013633. doi: 10.1126/science.abb7269.", "ArticleIdList": ["10.1126/science.abb7269", "PMC7164391", "32245784"]}, {"Citation": "Hu JP, He HQ, Tang DY, Sun GF, Zhang YQ, Fan J, et al. Study on the interactions between diketo-acid inhibitors and prototype foamy virus integrase-DNA complex via molecular docking and comparative molecular dynamics simulation methods. J Biomol Struct Dyn. 2013;31(7):734\u2013747. doi: 10.1080/07391102.2012.709458.", "ArticleIdList": ["10.1080/07391102.2012.709458", "22913375"]}, {"Citation": "Lee H. All-Atom Simulations and Free-Energy Calculations of Antibodies Bound to the Spike Protein of SARS-CoV-2: The Binding Strength and Multivalent Hydrogen-Bond Interactions. Adv Theor Simul. 2021;4. doi: 10.1002/adts.202100012.", "ArticleIdList": ["PMC8250114", "34230907"]}, {"Citation": "Pulliam JRC, van Schalkwyk C, Govender N, Gottberg A, Cohen C, Groome M, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv. 2021. doi: 10.1101/2021.11.11.21266068.", "ArticleIdList": ["PMC8995029", "35289632"]}, {"Citation": "Zhou T, Tsybovsky Y, Gorman J, Micah R, Gabriele C, Chuang GY, et al. Cryo-EM Structures of SARS-CoV-2 spike without and with ACE2 reveal a pH-dependent switch to mediate endosomal positioning of receptor-binding domains. Cell Host Microbe. 2020;28(6):867\u2013879. doi: 10.1016/j.chom.2020.11.004.", "ArticleIdList": ["10.1016/j.chom.2020.11.004", "PMC7670890", "33271067"]}, {"Citation": "Liu D, Ju C, Han C, Shi R, Chen XH, Duan D, et al. Nanozyme chemiluminescence paper test for rapid and sensitive detection of SARS-CoV-2 antigen. Biosens Bioelectron. 2021;173:112817. doi: 10.1016/j.bios.2020.112817.", "ArticleIdList": ["10.1016/j.bios.2020.112817", "PMC7661926", "33221508"]}, {"Citation": "Fratev F. N501Y and K417N Mutations in the Spike Protein of SARS-CoV-2 Alter the Interactions with Both hACE2 and Human-Derived Antibody: A Free Energy of Perturbation Retrospective Study. J Chem Inf Model. 2021;61(12):6079\u20136084. doi: 10.1021/acs.jcim.1c01242.", "ArticleIdList": ["10.1021/acs.jcim.1c01242", "34806876"]}, {"Citation": "Walls AC, Park YJ, Tortorici MA, Wall A, Guire AT, Veesier D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281\u2013292. doi: 10.1016/j.cell.2020.02.058.", "ArticleIdList": ["10.1016/j.cell.2020.02.058", "PMC7102599", "32155444"]}, {"Citation": "Mansbach RA, Chakraborty S, Nguyen K, Montefiori DC, Korber B, Gnanakaran S. The SARS-CoV-2 Spike variant D614G favors an open conformational state. Sci Adv. 2021;7(16):eabf3671. doi: 10.1126/sciadv.abf3671.", "ArticleIdList": ["10.1126/sciadv.abf3671", "PMC8051874", "33863729"]}, {"Citation": "Scientific American Arabic. How Scientists Can Update COVID Vaccines against Omicron? 2021. https://www.scientificamerican.com/article/how-scientists-can-update-covid-vaccines-against-omicron/. Accessed 09 Dec 2021."}, {"Citation": "Xie X, Liu Y, Liu J, Zhang XW, Zou J, Camila R, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited serum. Nat Med. 2021;27(4):620\u2013621. doi: 10.1038/s41591-021-01270-4.", "ArticleIdList": ["10.1038/s41591-021-01270-4", "33558724"]}, {"Citation": "Liu Z, VanBlargan LA, Bloyet LM, Rothlaur PW, Chen RE, Stumpf S, et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021;29(3). doi: 10.1016/j.chom.2021.01.014.", "ArticleIdList": ["PMC7839837", "33535027"]}, {"Citation": "Wu K, Choi A, Koch M, Elbashir S, Ma LZ, Lee D, et al. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. Vaccine. 2021;39(51):7394\u20137400. doi: 10.1101/2021.04.13.439482.", "ArticleIdList": ["10.1101/2021.04.13.439482", "PMC8572694", "34815117"]}, {"Citation": "Globe Newswire. Gritstone Oncology, Inc. 2021. https://www.globenewswire.com/fr/news-release/2021/01/19/2160371/0/en/Gritstone-Advances-Second-Generation-COVID-19-Vaccine-CORAL-Program-with-Support-from-NIAID-Program-has-Potential-to-Protect-Against-Mutant-Variants-of-SARS-CoV-2.html. Accessed 19 Jan 2021."}, {"Citation": "Mishra T, Joshi G, Kumar A, Dalavi R, Pandey P, Shukla S, et al. B. 1.617. 3 SARS CoV-2 spike E156G/\u0394157\u2013158 mutations contribute to reduced neutralization sensitivity and increased infectivity. bioRxiv. 2021. doi: 10.1101/2021.10.04.463028.", "ArticleIdList": ["0"]}, {"Citation": "Cerutti G, Guo Y, Wang P, Nair MS, Wang M, Huang Y, et al. Neutralizing antibody 5\u20137 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain. Cell Rep. 2021;37(5):109928. doi: 10.1016/j.celrep.2021.109928.", "ArticleIdList": ["10.1016/j.celrep.2021.109928", "PMC8519878", "34706271"]}, {"Citation": "Yuan M, Wu NC, Zhu X, Lee CC, So RT, Huibin L, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020;368(6491):630\u2013633. doi: 10.1126/science.abb7269.", "ArticleIdList": ["10.1126/science.abb7269", "PMC7164391", "32245784"]}, {"Citation": "Cao Y, Wang J, Jian F, Xiao T, Song W L, Yisimayi A, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2021;1\u20139.doi:10.1038/s41586-021-04385-3.", "ArticleIdList": ["PMC8866119", "35016194"]}, {"Citation": "Kannan SR, Spratt AN, Sharma K, Chand HS, Byrareddy SN, Singh K. Omicron SARS-CoV-2 variant: unique features and their impact on pre-existing antibodies. J Autoimmun. 2022;126:102779. doi: 10.1016/j.jaut.2021.102779.", "ArticleIdList": ["10.1016/j.jaut.2021.102779", "PMC8666303", "34915422"]}, {"Citation": "Kumar S, Thambiraja TS, Karuppanan K, Subramaniam G. Omicron and Delta variant of SARS-CoV-2: a comparative computational study of spike protein. J Med Virol. 2021;1:1\u20139. doi: 10.1002/jmv.27526.", "ArticleIdList": ["10.1002/jmv.27526", "34914115"]}, {"Citation": "Sadek A, Zaha D, Ahmed MS. Structural insights of SARS-CoV-2 spike protein from Delta and Omicron variants. bioRxiv. 2021;1:1\u201318. doi: 10.1101/2021.12.08.471777.", "ArticleIdList": ["10.1101/2021.12.08.471777"]}, {"Citation": "Luan J, Lu Y, Jin X, Zhang LL. Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection. Biochem Bioph Res Co. 2020;526(1):165\u2013169. doi: 10.1016/j.bbrc.2020.03.047.", "ArticleIdList": ["10.1016/j.bbrc.2020.03.047", "PMC7102515", "32201080"]}, {"Citation": "Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. J Intensive Care Med. 2020;46(4):586\u2013590. doi: 10.1007/s00134-020-05985-9.", "ArticleIdList": ["10.1007/s00134-020-05985-9", "PMC7079879", "32125455"]}, {"Citation": "Neerukonda SN, Vassell R, Lusvarghi S, Wang R, Echegaray F, Bentley L, et al. SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity. Viruses. 2021;13(12):2485. doi: 10.3390/v13122485.", "ArticleIdList": ["10.3390/v13122485", "PMC8707919", "34960755"]}, {"Citation": "Chen J, Wang R, Gilby NB, Wei GW. Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model. 2022;62(2):412\u201322. 10.1021/acs.jcim.1c01451.", "ArticleIdList": ["PMC8751645", "34989238"]}, {"Citation": "Hussain M, Jabeen N, Amanullah A, Baig AA, Aziz B, Shabbir S, et al. Molecular docking between human TMPRSS2 and SARS-CoV-2 spike protein: conformation and intermolecular interactions. Aims Microbiol. 2020;6(3):350\u2013360. doi: 10.3934/microbiol.2020021.", "ArticleIdList": ["10.3934/microbiol.2020021", "PMC7535071", "33029570"]}, {"Citation": "Gupta R. SARS-CoV-2 Omicron spike mediated immune escape and tropism shift. Res Square. 2022;1:1\u201319. doi: 10.21203/rs.3.rs-1191837/v1.", "ArticleIdList": ["10.21203/rs.3.rs-1191837/v1"]}, {"Citation": "Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA, Muley H, et al. SARS-CoV-2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020;39(10):e105114. doi: 10.15252/embj.20105114.", "ArticleIdList": ["10.15252/embj.20105114", "PMC7232010", "32246845"]}, {"Citation": "Mannar D, Saville JW, Zhu X, Sricastava SS, Berezuk AM, Zhou S, et al. Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding. Cell Rep. 2021;37(12):110156. doi: 10.1016/j.celrep.2021.110156.", "ArticleIdList": ["10.1016/j.celrep.2021.110156", "PMC8642162", "34914928"]}, {"Citation": "Mannar D, Saville JW, Zhu X, Sricastava SS, Berzuk AM, Tuttle KS, et al. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science. 2022; eabn7760. doi: 10.1126/science.abn7760.", "ArticleIdList": ["PMC9799367", "35050643"]}, {"Citation": "Zhu Y, Yu D, Yan H, Chong HH, He YX. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity. J Virol. 2020;94(14):e00635\u201320. doi: 10.1101/2020.03.26.009233.", "ArticleIdList": ["10.1101/2020.03.26.009233", "PMC7343218", "32376627"]}, {"Citation": "Xie X, Han JB, Ma G, Feng XL, Li XH, Zou QC, et al. Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies. Zool Res. 2021;42(6):789\u2013791. doi: 10.24272/j.issn.2095-8137.2021.343.", "ArticleIdList": ["10.24272/j.issn.2095-8137.2021.343", "PMC8645883", "34704423"]}, {"Citation": "Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183:1024\u20131042. doi: 10.1016/j.cell.2020.09.037.", "ArticleIdList": ["10.1016/j.cell.2020.09.037", "PMC7494283", "32991844"]}, {"Citation": "Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409\u2013424. doi: 10.1038/s41579-021-00573-0.", "ArticleIdList": ["10.1038/s41579-021-00573-0", "PMC8167834", "34075212"]}, {"Citation": "Uriu K, Kimura I, Shirakawa K, Kondo AT, Nakada T, Nakagawa S, et al. Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum. New Engl J Med. 2021;385(25):2397\u20132399. doi: 10.1056/NEJMc2114706.", "ArticleIdList": ["10.1056/NEJMc2114706", "PMC8609602", "34731554"]}, {"Citation": "Tada T, Zhou H, Dcosta BM, Samanovic MI, Cornelius A, Herati RS, et al. Neutralization of Mu and C. 1.2 SARS-CoV-2 variants by vaccine-elicited antibodies in individuals with and without previous history of infection. bioRxiv. 2021;1:1\u201334. doi: 10.1101/2021.10.19.463727.", "ArticleIdList": ["10.1101/2021.10.19.463727"]}, {"Citation": "Wang L, Kainulainen MH, Jiang N, Di H, Bonenfant G, Mils L, et al. Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines. bioRxiv. 2021;1:1\u201322. doi: 10.1101/2021.11.24.469906.", "ArticleIdList": ["10.1101/2021.11.24.469906", "PMC9328008", "35896523"]}, {"Citation": "Muik A, Lui BG, Wallisch AK, Bacher M, Muhl J, Reinholz J, et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine\u2013elicited human sera. Science. 2022;eabn7591. doi: 10.1126/science.abn7591.", "ArticleIdList": ["PMC9836206", "35040667"]}, {"Citation": "Jeewandara C, Kamaladasa A, Pushpakumara PD, Jayathilaka D, Aberathna IS, Danasekara DRSR, et al. Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers. Nat Commun. 2021;12(1):1\u20139. doi: 10.1038/s41467-021-24579-7.", "ArticleIdList": ["10.1038/s41467-021-24579-7", "PMC8322137", "34326317"]}, {"Citation": "Bian L, Gao Q, Gao F, Wang Q, He Q, Wu X, et al. Impact of the Delta variant on vaccine efficacy and response strategies. Expert Rev Vaccines. 2021;20(10):1201\u20131209. doi: 10.1080/14760584.2021.1976153.", "ArticleIdList": ["10.1080/14760584.2021.1976153", "PMC8442750", "34488546"]}, {"Citation": "Huang B, Dai L, Wang H, Hu ZY, Yang XM, Tan WJ, et al. Neutralization of SARS-CoV-2 VOC 501Y. V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines. bioRxiv. 2021;1:1\u201312. doi: 10.1101/2021.02.01.429069.", "ArticleIdList": ["10.1101/2021.02.01.429069"]}, {"Citation": "Vacharathit V, Aiewsakun P, Manopwisedjaroen S, Srisaowakarn C, Laopanupong T, Ludowyke N, et al. SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus neutralization in sera from CoronaVac vaccinees and naturally infected COVID-19 patients. medRxiv. 2021;1:1\u201315. doi: 10.1101/2021.07.10.21260232.", "ArticleIdList": ["10.1101/2021.07.10.21260232"]}, {"Citation": "Mahase E. Covid-19: Pfizer\u2019s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021;375:n2713. doi: 10.1136/bmj.n2713.", "ArticleIdList": ["10.1136/bmj.n2713", "34750163"]}, {"Citation": "Mahase E. Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk MSD reports. BMJ. 2021;375:n2422. doi: 10.1136/bmj.n2422.", "ArticleIdList": ["10.1136/bmj.n2422", "34607801"]}, {"Citation": "Ansems K, Grundeis F, Dahms K, Dodd LE, Mehta AK, Zingman BS, et al. Remdesivir for the treatment of COVID-19. Cochrane DB Syst Rev. 2021;383(19):1813\u20131826. doi: 10.1002/14651858.CD014962.", "ArticleIdList": ["10.1002/14651858.CD014962"]}, {"Citation": "Andrew W, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;W1:W296\u2013W303. doi: 10.1093/nar/gky427.", "ArticleIdList": ["10.1093/nar/gky427", "PMC6030848", "29788355"]}, {"Citation": "Xiao T, Lu J, Zhang J, Johnson RI, McKay LG, Storm N, et al. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro. bioRxiv. 2020;1:1\u201330. doi: 10.1101/2020.09.18.301952.", "ArticleIdList": ["10.1101/2020.09.18.301952", "PMC7895301", "33432247"]}, {"Citation": "Petra M, Kemp S, Dhar MS, Papa G, Meng B, Mishra S, et al. SARS-CoV-2 B.1.617.2 Delta variant emergence and vaccine breakthrough. Nat Portfolio. 2021;1:1\u201329. doi: 10.21203/rs.3.rs-637724/v1.", "ArticleIdList": ["10.21203/rs.3.rs-637724/v1"]}, {"Citation": "McCallum M, Czudnochowski N, Rosen LE, Zepeda SK, Bowen JE, Walls AC, et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science. 2022;eabn8652. doi: 10.1126/science.abn8652.", "ArticleIdList": ["PMC9427005", "35076256"]}, {"Citation": "Yuan S, Chan HCS, Hu Z. Using PyMOL as a platform for computational drug design Wiley Interdisciplinary Reviews. Comput Mol Sci. 2017;7(2):e1298. doi: 10.1002/wcms.1298.", "ArticleIdList": ["10.1002/wcms.1298"]}, {"Citation": "Zundert GCP, Rodrigues J, Trellet M, Schmitz C, Kastritis PL, Karaca E, et al. The HADDOCK2.2 webserver: User-friendly integrative modeling of biomolecular complexes. J Mol Biol. 2015;428:720\u2013725. doi: 10.1016/j.jmb.2015.09.014.", "ArticleIdList": ["10.1016/j.jmb.2015.09.014", "26410586"]}, {"Citation": "Bryan J, Beldar S, Seitova A, Hutchinson A, Manner D, Li Y, et al. Structure, activity and inhibition of human TMPRSS2, a protease implicated in SARS-CoV-2 activation. bioRxiv. 2021;1:1\u201319.", "ArticleIdList": ["35676539"]}, {"Citation": "Honorato RV, Koukos PI, Jim\u00e9nez-Garc\u00eda B, Tsaregorodtsev A, Verlato M, Giachetti A, et al. Structural biology in the clouds: the WeNMR-EOSC Ecosystem. Front Mol Biosci. 2021;8:729513. doi: 10.3389/fmolb.2021.729513.", "ArticleIdList": ["10.3389/fmolb.2021.729513", "PMC8356364", "34395534"]}, {"Citation": "Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem. 2004;25:1157\u20131174. doi: 10.1002/jcc.20035.", "ArticleIdList": ["10.1002/jcc.20035", "15116359"]}, {"Citation": "Case DA, Yandong H, Walker RC, Simmerling C, Roitberg A, Merz KM, AMBER,, et al. University of California. San Francisco. 2019;2010:1\u2013900."}, {"Citation": "Jorgensen WL, Chandrasekhar J, Madura JD. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983;79(2):926\u2013935. doi: 10.1063/1.445869.", "ArticleIdList": ["10.1063/1.445869"]}, {"Citation": "Miyamoto S, Kollman PA. Settle: an analytical version of the SHAKE and RATTLE algorithm for rigid water models. J Comput Chem. 1992;13(8):952\u2013962. doi: 10.1002/jcc.540130805.", "ArticleIdList": ["10.1002/jcc.540130805"]}, {"Citation": "Humphrey W, Dalke A, Schulten K. VMD-Visual Molecular Dynamics. J Mol Graph. 1996;14(1):33\u201338. doi: 10.1016/0263-7855(96)00018-5.", "ArticleIdList": ["10.1016/0263-7855(96)00018-5", "8744570"]}, {"Citation": "Laskowski RA, Swindells MB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model. 2011;51:2778\u20132786. doi: 10.1021/ci200227u.", "ArticleIdList": ["10.1021/ci200227u", "21919503"]}, {"Citation": "Closter J M, Peters B, Nielsen M, Marcatili P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res. 2017;45. doi: 10.1093/nar/gkx352.", "ArticleIdList": ["PMC5570230", "28472356"]}, {"Citation": "Liang S, Zheng D, Zhang C, Zacharias Me. Prediction of antigenic epitopes on protein surfaces by consensus scoring. BMC Bioinformatics. 2009;302:1\u201310. doi: 10.1186/1471-2105-10-302.", "ArticleIdList": ["PMC2761409", "19772615"]}, {"Citation": "Duan H, Liu X, Zhuo W, Meng J, Gu J, Sun X, et al. 3D-QSAR and molecular recognition of Klebsiella pneumoniae NDM-1 inhibitors. Mol Simulat. 2019;45(9):694\u2013705. doi: 10.1080/08927022.2019.1579327.", "ArticleIdList": ["10.1080/08927022.2019.1579327"]}, {"Citation": "Feig M, Karanicolas J, Brooks CL., III MMTSB Tool Set: enhanced sampling and multiscale modeling methods for applications in structural biology. J Mol Graph Model. 2004;22:377\u2013395. doi: 10.1016/j.jmgm.2003.12.005.", "ArticleIdList": ["10.1016/j.jmgm.2003.12.005", "15099834"]}, {"Citation": "Eisenhaber F, Lijnzaad P, Argos P, Sander C, Scharf M. The double cubic lattice method: efficient approaches to numerical integration of surface area and volume and to dot surface contouring of molecular assemblies. J Comput Chem. 1995;16(3):273\u2013284. doi: 10.1002/jcc.540160303.", "ArticleIdList": ["10.1002/jcc.540160303"]}, {"Citation": "Robert K, Baker NA, McCammon JA. iAPBS: a programming interface to the adaptive Poisson-Boltzmann solver. Comput Sci Discov. 2012;5(1):015005. doi: 10.1088/1749-4699/5/1/015005.", "ArticleIdList": ["10.1088/1749-4699/5/1/015005", "PMC3419494", "22905037"]}, {"Citation": "Olsson MH, S\u00f8ndergaard CR, Rostkowski M, Jensen JH. PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. J Chem Theory and Comput. 2011;7(2):525\u2013537. doi: 10.1021/ct100578z.", "ArticleIdList": ["10.1021/ct100578z", "26596171"]}, {"Citation": "Ashkenazy H, Abadi S, Martz E, Chay O, Mayrose I, Pupko T, et al. ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules. Nucleic Acids Res. 2016;44(W1):W344\u2013W350. doi: 10.1093/nar/gkw408.", "ArticleIdList": ["10.1093/nar/gkw408", "PMC4987940", "27166375"]}, {"Citation": "Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res. 2000;33(12):889\u2013897. doi: 10.1002/chin.200110299.", "ArticleIdList": ["10.1002/chin.200110299", "11123888"]}, {"Citation": "Simonson T. Macromolecular electrostatics: continuum models and their growing pains. Curr Opin Struc Biol. 2001;11(2):243\u2013252. doi: 10.1016/S0959-440X(00)00197-4.", "ArticleIdList": ["10.1016/S0959-440X(00)00197-4", "11297935"]}, {"Citation": "Weiser J, Shenkin PS, Still WC. Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO). J Comput Chem. 1999;20(2):217\u201330. 10.1002/(SICI)1096-987X(19990130)20:2%3c217::AID-JCC4%3e3.0.CO;2-A."}, {"Citation": "Tippmann S. Programming tools: Adventures with R. Nature. 2015;517(7532):109\u2013110. doi: 10.1038/517109a.", "ArticleIdList": ["10.1038/517109a", "25557714"]}, {"Citation": "Ciccarelli FD, Doerks T, Von Mering C, Creevey CJ, Snel B, Bork P. Toward automatic reconstruction of a highly resolved tree of life. Science. 2006;311:1283\u20131287. doi: 10.1126/science.1123061.", "ArticleIdList": ["10.1126/science.1123061", "16513982"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "3", "Day": "2"}, {"Year": "2022", "Month": "3", "Day": "25"}, {"Year": "2022", "Month": "4", "Day": "24", "Hour": "20", "Minute": "12"}, {"Year": "2022", "Month": "4", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "4", "Day": "25", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "4", "Day": "24"}], "PublicationStatus": "epublish", "ArticleIdList": ["35461370", "PMC9034971", "10.1186/s43556-022-00074-3", "10.1186/s43556-022-00074-3"]}}], "PubmedBookArticle": []}